Go to the list of all blogs
Scott Bell's Avatar
published in Blogs
Nov 19, 2026
TickeronGET DAILY SIGNALS
Why Is Regentis Biomaterials (RGNT) Stock Down -12.28% Today?

Why Is Regentis Biomaterials (RGNT) Stock Down -12.28% Today?

Key Takeaways

  • RGNT shares fell 12.28% in Thursday's session, sliding to $1.00 from a prior close of $1.14 — a decline of $0.14 that pushed the stock to a fresh all-time low.
  • No verified company-specific news — no press release, regulatory decision, financing, or analyst action — was published around the move.
  • Secondary drivers are structural: extremely thin liquidity, a small 4.26 million-share float, and a months-long pattern of lower highs dating back to the December 2025 IPO.
  • The decline is idiosyncratic rather than sector-driven; there was no orthopedic or medtech industry catalyst matching the timing or magnitude.
  • News Significance Score: 18/100 — No verified catalyst and a move roughly 3.6 times the stock's typical daily swing.
  • Traders are watching whether the $1.00 round number holds and whether the company updates investors on pivotal trial enrollment before year-end.
  • Deeper detail on Price Targets, Earnings, and Forecast data is available on the dedicated ticker pages.
  • Readers can also review Trending AI Robots to see which automated strategies are performing best in the current market.

Regentis Biomaterials Shares Sink to a Record Low

Regentis Biomaterials Ltd. (RGNT) is a Herzliya, Israel–based regenerative medicine company focused on orthopedic tissue repair. Its lead product candidate, GelrinC, is a cell-free, off-the-shelf hydrogel implant that is injected as a liquid into a knee cartilage lesion and cured with UV light, then gradually resorbed as new tissue forms. GelrinC holds CE Mark approval in Europe and is being evaluated in a U.S. pivotal Phase III trial under an FDA investigational device exemption.

In Thursday's trading, the stock changed hands at $1.00, down $0.14, or 12.28%, from the previous session's close of $1.14. The direction was decisively lower, and the intraday print of $1.00 marked the weakest level since the company listed on the NYSE American at $8.00 per share in December 2025. No verified news or fundamental development was identified to explain the decline; the move instead reflects a continuation of a downtrend that has been in place for months.

No verified news or fundamental catalyst found

No verified news or fundamental catalyst found to account for Thursday's drop. No press release, SEC filing, pricing announcement, regulatory update, or analyst rating change was published in the window leading into the move, and the company's most recent material disclosure remains its November 9 announcement of a four-year exclusive distribution agreement for GelrinC in Israel. That release lifted the shares at the time but has not produced follow-through buying.

The most plausible technical explanation is a liquidity vacuum layered on top of persistent selling pressure. Average daily volume over the past 20 sessions is roughly 47,000 shares, and the public float is only about 4.26 million shares — a combination that allows relatively small orders to move the quote meaningfully. Thursday's activity was not visibly heavy in the tape, which is consistent with a thin order book rather than institutional distribution. The stock has also traded below both its 50-day and 200-day moving averages, near $1.61 and $2.68 respectively, for weeks, keeping trend-following and momentum-driven flows on the sell side.

Recent News Flow Provides No Fresh Support

The company's disclosure cadence has been steady but incremental. First-half 2026 results, reported in mid-September, showed progress in the U.S. pivotal trial with enrollment targeted for completion around year-end 2026, alongside European commercialization readiness and a previously announced manufacturing process that lifts production yield by 400%. Each of those items was constructive but small relative to the scale of the company's cash needs, and none represented the kind of binary event — pivotal data or an FDA decision — that typically resets a micro-cap device story. Investors have also weighed the dilution history: shares outstanding rose sharply over the past year following a $6.5 million private placement and the IPO itself.

Market Context and Trading Activity

Volume on Thursday was not materially elevated relative to the roughly 46,000-share daily average, underscoring that a modest number of trades is enough to displace the price in a name this illiquid. The move was similarly not mirrored by broad indices or by large-cap orthopedic and medical-device peers, which is consistent with a company-specific repricing rather than a sector rotation or macro event. Technically, the session broke the prior 52-week low of $1.14 with little support underneath, and the $1.00 round number now becomes the reference level traders will monitor. The stock's softness places it roughly 87% below its IPO price and well under its 52-week high of $15.50.

News Significance Score

The score is measured on a 0-to-100 scale, where 0 reflects no meaningful news and a routine price move, and 100 reflects transformative news paired with an extreme, rare move. Regentis earns 18 out of 100.

The news component is essentially absent: no verified catalyst existed on Thursday, leaving only technical and flow-driven pressure to explain the session. The price component is moderate. Thursday's 12.28% decline was about 3.6 times the stock's average absolute daily move of roughly 3.4% across the last 60 sessions, and a move of that size occurred only once in that stretch — the 23% gain on September 21. With volume unremarkable, the two components combine into a low overall score.

What Comes Next for RGNT

Attention now centers on trial execution. Management has guided toward completing enrollment in the U.S. pivotal study around year-end 2026, and any update on that timetable — or on the pace of European commercialization following the Israeli distribution agreement — is the most likely near-term inflection point. No quarterly earnings date has been confirmed for the current period, and analyst coverage remains thin, with limited published estimates to anchor expectations.

Key risks include the company's cash runway relative to the cost of finishing a pivotal device trial, the potential need for additional capital that could dilute existing holders, and the possibility of further delays in the regulatory process. Upside would depend on clean data and a credible path to U.S. approval; downside remains tied to financing conditions and the illiquidity that amplifies moves in both directions.

Trending AI Robots

Tickeron's Trending AI Robots page highlights the automated trading strategies performing best under current market conditions. Tickeron offers hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers earn a place in this curated section. Bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the page offers a practical starting point for comparing approaches. Investors researching names like Regentis can explore the featured robots to see how systematic strategies are positioned right now.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: RGNT

Contributor

Scott Bell's AvatarScott Bell|Expert

I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking


RGNT's RSI Indicator recovers from oversold territory

The RSI Indicator for RGNT moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 10 similar instances when the indicator left oversold territory. In 9 of the 10 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for RGNT just turned positive on November 02, 2026. Looking at past instances where RGNT's MACD turned positive, the stock continued to rise in 5 of 6 cases over the following month. The odds of a continued upward trend are 83%.

Following a +11.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where RGNT advanced for three days, in 18 of 26 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.

RGNT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on RGNT as a result. In 13 of 13 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RGNT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for RGNT entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.088) is normal, around the industry mean (4.964). P/E Ratio (-0.050) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (56.876).

The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. RGNT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RGNT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 9.78B. The market cap for tickers in the group ranges from 126 to 159.96B. ISRG holds the highest valuation in this group at 159.96B. The lowest valued company is HGYMF at 126.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -5%. For the same Industry, the average monthly price growth was -2%, and the average quarterly price growth was 7%. RVP experienced the highest price growth at 12%, while ZJYL experienced the biggest fall at -31%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 20%. For the same stocks of the Industry, the average monthly volume growth was 16% and the average quarterly volume growth was -32%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 54
Price Growth Rating: 51
SMR Rating: 81
Profit Risk Rating: 94
Seasonality Score: 23 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsOther

Industry
N/A
Address
60, Medinat Hyahudim
Phone
+972 99601917
Employees
7
Web
https://www.regentis.co.il
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.